Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $35 million, down 5% year-over-year but up 2% sequentially from Q3 2025 [17] - Adjusted EBITDA for Q4 was $8.7 million, with an adjusted net income of $3.4 million and adjusted EPS of 16 cents per share [18] - Full year 2025 revenue was $137.4 million, down 4% from 2024, but TRCV grew by 8% in 2025, indicating potential revenue growth in 2026 [19] Business Line Data and Key Metrics Changes - Total Recurring Contract Value (TRCV) reached $144 million, up 8% year-over-year, marking the fifth consecutive quarter of sequential TRCV growth [4][17] - New sales increased by 86% year-over-year, reflecting effective sales strategies and customer engagement [5] Market Data and Key Metrics Changes - NRC Health serves 74% of the top 100 health systems in the U.S., indicating strong market presence and trust [9] - The company reported a Net Promoter Score of 68, reflecting high customer satisfaction [9] Company Strategy and Development Direction - The company is focused on enhancing its product portfolio and customer engagement strategies to drive growth [5][12] - Investment in AI and product innovation is a strategic priority to deepen differentiation and expand the addressable market [13] - The leadership team has been strengthened to support growth, with a focus on combining healthcare operations expertise with technology [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to create lasting value amidst the complexities of the healthcare landscape [24] - The company anticipates that the restructuring of its go-to-market strategy will provide a meaningful tailwind through 2026 [12] Other Important Information - The company maintained a disciplined approach to capital allocation, balancing investments in growth with returns to shareholders through dividends and share repurchases [21][22] - The adjusted EBITDA margin for 2025 was 29%, showcasing strong profitability despite revenue decline [19] Q&A Session Summary - No specific questions or answers were provided in the content, indicating a focus on the presentation rather than an interactive Q&A session.

Q3 2025 Financial Performance - Revenue for Q3 2025 reached $4,100 million, a 5.2% increase AFx (actual foreign exchange rates) and 3.9% increase CFx (constant currency) compared to $3,896 million in Q3 2024[12] - Adjusted EBITDA for Q3 2025 was $949 million, a 1.1% increase AFx compared to $939 million in Q3 2024[12] - Adjusted Diluted EPS for Q3 2025 was $3.00, a 5.6% increase AFx compared to $2.84 in Q3 2024[12] - Net income attributable to IQVIA Holdings Inc was $331 million in Q3 2025, compared to $285 million in Q3 2024[31] Year-to-Date (YTD) Performance - YTD Revenue for 2025 reached $11,946 million, a 4.4% increase AFx and 3.7% increase CFx compared to $11,447 million in 2024[15] - YTD Adjusted EBITDA for 2025 was $2,742 million, compared to $2,688 million in 2024[17] - YTD Adjusted Diluted Earnings per Share was $8.50, compared to $8.02 in 2024[17] Segment Performance (Q3 2025) - Technology & Analytics Solutions revenue was $1,631 million, a 5.0% increase AFx compared to $1,554 million in Q3 2024[15] - Research & Development Solutions revenue was $2,260 million, a 4.5% increase AFx compared to $2,162 million in Q3 2024[15] - Contract Sales & Medical Solutions revenue was $209 million, a 16.1% increase AFx compared to $180 million in Q3 2024[15] R&D Solutions Bookings and Backlog - R&D Solutions backlog increased by 4.1% from $31.1 billion in Q3 2024 to $32.4 billion in Q3 2025[21] Balance Sheet and Cash Flow - Cash & Cash Equivalents totaled $1,814 million[23] - Free Cash Flow for Q3 2025 was $772 million[23] Full Year 2025 Guidance - The company projects full-year 2025 revenue between $16,150 million and $16,250 million[26] - The company projects full-year 2025 Adjusted EBITDA between $3,775 million and $3,800 million[26] - The company projects full-year 2025 Adjusted Diluted EPS between $11.85 and $11.95[26]